# Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

> **NCT00810576** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00810576
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2012-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810576, "Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00810576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*